Background

Methods
Results
Telemonitoring is based on transmission of patients' blood glucose measurements to healthcare providers through a modem. Its use can result in improvement of glycemic control in inefficiently insulin-treated patients with diabetes mellitus (DM). Aim of our study was to determine whether the improvement of HbA1c, observed in inefficiently insulin-treated patients with type 1 and type 2 DM on a telemonitoring system, had a lasting effect following its discontinuation.
 Data were transmitted from the glucose-meters to our clinic computers via modem.  Communication with the patients was achieved with e-mails and mobile-phone text messages (SMS) through integrated software (Telemedicor).  Telemonitoring period was 6 months.  HbA1c and BMI were evaluated at enrollment, 3 and 6 months, as well as 6 months after discontinuation of the telemonitoring.  Telemonitoring can result in improved compliance especially in patients with HbA1c>10%. This is reflected in the reduction of HbA1c levels compared to controls.  Beneficial effect on HbA1c is sustained, though blunted, 6 months after terminating the intervention.  Visits of outpatient departments are reduced, resulting in lower cost and less patient inconvenience.
 Significant reduction in HbA1c was
observed at 3 and 6 months in patients and controls (Table 2) .  Compared to controls, a significant reduction in HbA1c was also observed in the group of patients with an initial HbA1c >10% at 3 months: 6.83±1.06% vs 8.45±0.87% as well as at 6 months: 6.7±1% vs 8.17±1.21% (p<0.001) and with an initial HbA1c <10% at 3 months: 7.02±0.67% vs 7.72±0.75% as well as at 6 months: 6.86±0.65% vs 7.52±0.86% (p<0.01) (Fig. 2) .  Six months after discontinuation of the telemonitoring, patients' HbA1c levels deteriorated (Table 2 ).  Significant increase was observed in both groups of patients with HbA1c >10% (7.35±1.35, p=0.001) and HbA1c <10% (7.17± 0.62, p=0.006) (Fig. 1) .
 Patients' inclusion criteria: insufficient control of DM (HbA1c>7.5%), distance from specialized medical facilities or recent hospitalization for DM.  Controls: insufficiently insulin-treated DM patients on regular follow-up at the outpatient department. Table 2 . HbA1c levels at 0, 3, 6 months and 6 months after discontinuation (12 months) of the telemonitoring (p1: enrollment vs 3months, p2 enrollment vs 6 months, p3 enrollment vs 12 months). 
